[HTML][HTML] Anti-tuberculosis treatment strategies and drug development: challenges and priorities

VA Dartois, EJ Rubin - Nature Reviews Microbiology, 2022 - nature.com
Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis

JP Ernest, N Strydom, Q Wang, N Zhang… - Annual review of …, 2021 - annualreviews.org
Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

[PDF][PDF] Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis

J Larkins-Ford, T Greenstein, N Van, YN Degefu… - Cell systems, 2021 - cell.com
Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis

A Richter, G Narula, I Rudolph, RW Seidel… - …, 2022 - Wiley Online Library
Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently
under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic …

[HTML][HTML] Lactate metabolism and signaling in tuberculosis and cancer: a comparative review

D Kiran, RJ Basaraba - Frontiers in Cellular and Infection …, 2021 - frontiersin.org
Infection with Mycobacterium tuberculosis (Mtb) leading to tuberculosis (TB) disease
continues to be a major global health challenge. Critical barriers, including but not limited to …

Pharmacodynamics and bactericidal activity of bedaquiline in pulmonary tuberculosis

MA Lyons - Antimicrobial Agents and Chemotherapy, 2022 - Am Soc Microbiol
Bedaquiline is a diarylquinoline antimycobacterial drug and a key component of several
regimens in clinical development for the treatment of tuberculosis (TB) but with ongoing …

[HTML][HTML] Pharmacometrics in tuberculosis: progress and opportunities

JJ Wilkins, EM Svensson, JP Ernest, RM Savic… - International Journal of …, 2022 - Elsevier
Tuberculosis (TB) remains one of the leading causes of death by a communicable agent,
infecting up to one-quarter of the world's population, predominantly in disadvantaged …

[HTML][HTML] Advances in clinical trial design: weaving tomorrow's TB treatments

C Lienhardt, A Nunn, R Chaisson, AA Vernon… - PLoS …, 2020 - journals.plos.org
Advances in clinical trial design: Weaving tomorrow’s TB treatments | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease

V Dartois, T Dick - Nature Reviews Drug Discovery, 2024 - nature.com
Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Advancing human in vitro pulmonary disease models in preclinical research: opportunities for lung-on-chips

A Artzy-Schnirman, CM Lehr… - Expert Opinion on Drug …, 2020 - Taylor & Francis
The past years have witnessed concerted efforts across the respiratory community to
establish more relevant in vitro preclinical tools for pulmonary research [1-3]. A strong …